ONE YEAR ESTROGEN/PROGESTIN IMPLANT

Information

  • Research Project
  • 6016833
  • ApplicationId
    6016833
  • Core Project Number
    R43AG017413
  • Full Project Number
    1R43AG017413-01
  • Serial Number
    17413
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 25 years ago
  • Project End Date
    2/28/2001 - 23 years ago
  • Program Officer Name
    SHERMAN, SHERRY
  • Budget Start Date
    9/1/1999 - 25 years ago
  • Budget End Date
    2/28/2001 - 23 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/6/1999 - 25 years ago
Organizations

ONE YEAR ESTROGEN/PROGESTIN IMPLANT

This program seeks to develop a one year biodegradable estrogen/progestin implant for postmenopausal hormone replacement therapy. The program will utilize a proven hormone combination, estradiol and levonorgestrel. It has been shown that side effects of estrogen therapy can be lowered by administering a progestin with the estrogen. Both hormones will be incorporated into an innovative implant design already under development by BIOTEK to deliver pure levonorgestrel as a maintenance contraceptive. The new implant is thermoformed from very high molecular weight poly-L-lactide, using a method which minimizes degradation during manufacture. The implant has a hormone-loaded outer shell for efficient drug delivery and a pure polymer core for mechanical strength. The implant will biodegrade if left in place for more than one year, but it can be surgically removed for medical reasons at earlier times. With no need to keep track of daily dosing, and little reason to anticipate an unpleasant removal episode, both women and doctors should welcome such implants as a convenient new form of estrogen replacement therapy combining almost effortless compliance with stable hormone levels. PROPOSED COMMERCIAL APPLICATIONS: The proposed work involves incorporating a drug into the outer portion of a strong, easily administered implant which biodegrades when left in the body for more than a year. The same technique could be useful for delivery of other chronically administered hormones and maintenance medications.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R43
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    BIOTEK, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES